Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- RM 499 gp 38 T1 ? extra-cellular CD 9 44 IL22 IL6 IFN? TGF? MCF7 CLEC2
- Product Overview:
Podoplanin is a transmembrane glycoprotein that has roles in development, immunology, and cancer.{64186,64187} It is composed of a glycosylated extracellular domain, which is critical for podoplanin-induced platelet activation, a single transmembrane region that associates with CD9 and CD44, and a short cytoplasmic tail that interacts with the ezrin-radixin-moesin (ERM) family of proteins to promote rearrangement of the actin cytoskeleton, as well as the epithelial-to-mesenchymal transition (EMT) during embryonic development.{64187} Podoplanin is expressed in various tissues during murine embryonic development but is predominantly restricted to stromal, lymphatic endothelial, and immune cells, lymphoid organs, and the heart and choroid plexus in the adult mouse.{64186,64187} Its expression is upregulated by various pro-inflammatory cytokines, including IL-22, IL-6, IFN-?, and TGF-?, and is increased in T cells, fibroblasts, and macrophages during inflammation. It localizes to the cell surface within lipid rafts where it interacts with numerous proteins to modulate cell adhesion and motility.{64186} Podoplanin binds to C-type lectin receptor 2 (CLEC-2), which is expressed on platelets, to induce platelet aggregation and activation, an effect that is inhibited by the interaction of podoplanin with CD9. Mice implanted with MCF-7 cells overexpressing podoplanin exhibit reduced primary tumor growth but enhanced tumor lymphangiogenesis and lymph node metastasis.{64188} Tumor podoplanin expression is associated with reduced overall survival in patients with oral squamous cell carcinoma (OSCC).{64189} Cayman’s Podoplanin Rabbit Monoclonal Antibody (Clone RM449) can be used for immunohistochemistry (IHC) and Western blot (WB) applications.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.